Statement of the German Pharmaceutical Industry Association (BPI e.V.)
Discussion about orphan drugs in the AMNOG procedure
In the 19th edition of InnoFo-TV, Dr. Pablo Serrano, member of the management board of the German Pharmaceutical Industry Association (BPI) and business unit manager innovation & research and biotechnology, and Dr. Matthias Wilken, managing director market access, markets and supply of the BPI, comment on the current discussion concerning the exceptional situation of orphan drugs in the AMNOG procedure.
Dr. Wilken explains that orphan drug procedures also have a solid data basis, as randomized clinical studies are very often available. Furthermore, he states that the drug expenditures for orphan drugs of the statutory health insurances have been stable at around 1% of the gross domestic product for years.
As a strategic consultancy in the healthcare sector with focus on rare diseases and their therapies, SKC consulting follows current developments and reacts agilely to any changes in its projects.
About the author
Karolin Priese
Associate Director Corporate & Product Marketing
Dipl.-Kauffrau
Associate Director Corporate & Product Marketing
Dipl.-Kauffrau
Fon: +49 511 64 68 14 – 0
Fax: +49 511 64 68 14 18
Fax: +49 511 64 68 14 18